source
- AstraZeneca's oral relaxin agonist shows positive phase 2b results in chronic heart failureAstraZeneca presented phase 2b data from its Luminara trial at the European Society of Cardiology Congress in Munich. The study evaluated the oral relaxin agonist AZD5462 in patients with chronic h…
- Experts urge FDA to boost transparency of complete response letters and refine master protocol guidanceA recent paper in the Journal of Law and the Biosciences outlines ways the FDA could better disclose complete response letters to the public, aiming to increase transparency for stakeholders. Indu…